Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Delandistrogene Moxeparvovec · Elevidys, SRP-9001

Gene therapy (AAV vector) · Gene replacement · developed by Sarepta Therapeutics

Approved FDA, Jun 2023
SRPT Developer
1 Registered trials

What is Delandistrogene Moxeparvovec?

Delandistrogene moxeparvovec is an adeno-associated virus (AAVrh74) vector-based gene therapy that delivers a DMD gene transgene encoding an engineered micro-dystrophin protein, which localizes to the sarcolemma of skeletal and cardiac muscle cells. It is studied in Duchenne muscular dystrophy, a disease caused by a mutation in the DMD gene that results in lack of functional dystrophin.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Elevidys, SRP-9001, ELEVIDYS
Drug type
Gene therapy (AAV vector)
Mechanism
Gene replacement
Therapy area
Musculoskeletal
Developer
Sarepta Therapeutics, Inc. (SRPT)
FDA status
Approved as Elevidys (June 22, 2023), BLA125781 · FDA label
UNII
2P6QV2ZE52

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 12, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07542314 Phase 4 Duchenne Muscular Dystrophy Recruiting SRPT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Duchenne Muscular Dystrophy

More from Sarepta Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SRPT page.

Follow SRPT, the company behind Delandistrogene Moxeparvovec

See SRPT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SRPT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.